A First-in-Human, Two-Part, Open-Label, Phase I/II Study of DSP107 in Subjects with Advanced Solid Tumors Including a Dose-Escalation Safety Study (Part 1) and Preliminary Efficacy Assessment of DSP107 as Monotherapy and in Combination with Atezolizumab (Part 2)

Is this Study for You?

Let's Get Started!


Part 1 of the study is open to all solid tumors. Part 2 of the study will evaluate the safety, tolerability and preliminary efficacy of DSP107, administered either as monotherapy or in combination with atezolizumab. The study will enrol subjects with NSCLC that is wildtype for actionable oncogenic driver mutations, and who have progressed following first line treatment with PD-1 or PD-L1 targeting agents having previously achieved a best response of stable disease or better measured after 12 weeks.



Type of Study



University of Colorado Hospital

Principal Investigator
Photograph of Antonio Jimeno,  MD, PhD

Antonio Jimeno, MD, PhD

Study ID

Protocol Number: 20-1690

More information available at ClinicalTrials.gov: NCT04440735


Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers